17-19 mars 2025
\nBoston, USA<\/p>\n
ENYO Pharma sera pr\u00e9sent au 7\u00e8me CKD Drug Development Summit, le seul \u00e9v\u00e9nement dirig\u00e9 par l’industrie d\u00e9di\u00e9 \u00e0 am\u00e9liorer la fronti\u00e8re des th\u00e9rapies pr\u00e9ventives et r\u00e9g\u00e9n\u00e9ratives pour cibler efficacement les maladies r\u00e9nales chroniques et \u00e9clairer les opportunit\u00e9s d’expansion des indications dans les troubles r\u00e9naux rares. <\/p>\n
https:\/\/ckd3-summit.com\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" 17-19 mars 2025 ENYO Pharma sera pr\u00e9sent au 7\u00e8me CKD Drug Development Summit, le seul \u00e9v\u00e9nement dirig\u00e9 par l’industrie d\u00e9di\u00e9 \u00e0 am\u00e9liorer la fronti\u00e8re des th\u00e9rapies pr\u00e9ventives et r\u00e9g\u00e9n\u00e9ratives pour cibler efficacement les maladies r\u00e9nales chroniques et \u00e9clairer les opportunit\u00e9s d’expansion des indications dans les troubles r\u00e9naux rares. <\/p>\n https:\/\/ckd3-summit.com\/<\/a><\/p>\n Lire la suite »<\/a><\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-5854","post","type-post","status-publish","format-standard","hentry","category-events-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"adm-cdubreuil","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/adm-cdubreuil\/"},"rttpg_comment":0,"rttpg_category":"\u00c9v\u00e9nements<\/a>","rttpg_excerpt":"17-19 mars 2025 Boston, USA ENYO Pharma sera pr\u00e9sent au 7\u00e8me CKD Drug Development Summit, le seul \u00e9v\u00e9nement dirig\u00e9 par l’industrie d\u00e9di\u00e9 \u00e0 am\u00e9liorer la fronti\u00e8re des th\u00e9rapies pr\u00e9ventives et r\u00e9g\u00e9n\u00e9ratives pour cibler efficacement les maladies r\u00e9nales chroniques et \u00e9clairer les opportunit\u00e9s d’expansion des indications dans les troubles r\u00e9naux rares. https:\/\/ckd3-summit.com\/Lire la suite »","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/5854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=5854"}],"version-history":[{"count":2,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/5854\/revisions"}],"predecessor-version":[{"id":5856,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/5854\/revisions\/5856"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=5854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=5854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=5854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nBoston, USA<\/p>\n